10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO, CA
FDA Approval of PALSONIFY TM (paltusotine) for the Treatment of Adults with Acromegaly
Reports Second Quarter 2025 Financial Results and Provides Business Update
Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline
Investor Presentation
Shareholder votes
Reports First Quarter 2025 Financial Results and Provides Business Update
Annual Report to Security Holders
Changes in Board, Management or Compensation
Q2
Q1
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities